Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma

Clinical Cancer Research

Volumn 21, Issue 10, 2015, Pages 2278-2288

  Zhang, Ling ^a   Morgan, Richard A ^a   Beane, Joal D ^a   Zheng, Zhili ^a   Dudley, Mark E ^a   Kassim, Sadik H ^a   Nahvi, Azam V ^a   Ngo, Lien T ^a   Sherry, Richard M ^a   Phan, Giao Q ^a   Hughes, Marybeth S ^a   Kammula, Udai S ^a   Feldman, Steven A ^a   Toomey, Mary Ann ^a   Kerkar, Sid P ^a   Restifo, Nicholas P ^a   Yang, James C ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; TRANSCRIPTION FACTOR NFAT;

ADOPTIVE TRANSFER; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CYTOKINE RELEASE; FEMALE; FEVER; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IL12 GENE; LIVER DYSFUNCTION; MALE; METASTATIC MELANOMA; MIDDLE AGED; PATIENT SAFETY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; TUMOR ASSOCIATED LEUKOCYTE; YOUNG ADULT; BIOSYNTHESIS; CELL CULTURE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHYSIOLOGY; SECONDARY; SKIN NEOPLASMS; TRANSCRIPTION INITIATION; TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; AGED; CELLS, CULTURED; FEMALE; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-12; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; TRANSCRIPTIONAL ACTIVATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929433571     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2085     Document Type: Article

References (28)

1. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011;17:4550-7.
2. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9.
3. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010;116:4099-102.
4. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptormodified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365: 725-33.
5. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial sarcoma and melanoma using genetically engineered lymphocytes reactivewith NY-ESO-1. J Clin Oncol 2011;29:917-24.
6. Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol 2012;13:722-8.
7. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993;178:1223-30.
8. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-Associated toxicity and interferon-gamma production. Blood 1997;90: 2541-8.
9. Kerkar SP,Goldszmid RS, Muranski P, ChinnasamyD, Yu Z, Reger RN, et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest 2011;121:4746-57.
10. Kerkar SP, Muranski P, Kaiser A, Boni A, Sanchez-Perez L, Yu Z, et al. Tumorspecific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res 2010;70:6725-34.
11. Chinnasamy D, Yu Z, Kerkar SP, Zhang L, Morgan RA, Restifo NP, et al. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors inmice. Clin Cancer Res 2012;18: 1672-83.
12. Pegram HJ, Lee JC,Hayman EG, Imperato GH, Tedder TF, SadelainM, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012;119:4133-41.
13. Zhang L, Feldman SA, Zheng Z, Chinnasamy N, Xu H, Nahvi AV, et al. Evaluaion of g-retrovial vectors thatmediate the inducible expression of IL-12 for clinical application.J Immunother 2012;35:430-9
14. Zhang L, Kerkar SP, Yu Z, Zheng Z, Yang S, Restifo NP, et al. Improving adoptive T-cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther 2011;19:751-9.
15. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298: 850-4.
16. Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, et al. Randomized selection design trial evaluating CD8+-enriched versus unseleected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol 2013;31:2152-9.
17. Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004;173:7125-30.
18. Yao X, AhmadzadehM, Lu YC, Liewehr DJ, Dudley ME, Liu F, et al. Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 2012;119:5688-96.
19. Anderson R, Macdonald I, Corbett T, Hacking G, Lowdell MW, Prentice HG. Construction and biological characterization of an interleukin-12 fusion protein (Flexi-12): delivery to acute myeloid leukemic blasts using adeno-Associated virus. Hum Gene Ther 1997;8:1125-35.
20. Wagner HJ, Bollard CM, Vigouroux S, Huls MH, Anderson R, Prentice HG, et al. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Ther 2004;11:81-91.
21. Orange JS, Wolf SF, Biron CA. Effects of IL12 on the response and susceptibility to experimental viral infections. J Immunol 1994;152: 1253-64.
22. Meyaard L, Hovenkamp E, Otto SA, Miedema F. IL12-induced IL10 production by human T cells as a negative feedback for IL12-induced immune responses. J Immunol 1996;156:2776-82.
23. Ansell SM, Geyer SM, Maurer MJ, Kurtin PJ, Micallef IN, Stella P, et al. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients. Clin Cancer Res 2006;12:6056-63.
24. Yang ZZ, Grote DM, Ziesmer SC, Niki T, Hirashima M, Novak AJ, et al. IL-12 upregulates TIM-3 expression and induces T-cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. Journal of Clinical Investigation 2012;122:1271-82.
25. Jin HT, Anderson AC, Tan WG, West EE,Ha SJ, Araki K, et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A 2010;107:14733-8.
26. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T-cell dysfunction inmelanoma patients. J Exp Med 2010;207:2175-86.
27. Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype inmice with disseminated acute myelogenous leukemia. Blood 2011;117:4501-10.
28. Pan WY, Lo CH, Chen CC, Wu PY, Roffler SR, Shyue SK, et al. Cancer immunotherapy using a membrane-bound interleukin-12 with B7-1 transmembrane and cytoplasmic domains. Mol Ther 2012;20:927-37.